Mohammed Rassool to Mycobacterium tuberculosis
This is a "connection" page, showing publications Mohammed Rassool has written about Mycobacterium tuberculosis.
Connection Strength
0,079
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,044
-
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 08; 9(8):897-908.
Score: 0,035